<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265534</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-014</org_study_id>
    <nct_id>NCT04265534</nct_id>
  </id_info>
  <brief_title>KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC</brief_title>
  <acronym>KEAPSAKE</acronym>
  <official_title>A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor&#xD;
      telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with&#xD;
      standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic&#xD;
      disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung&#xD;
      cancer (NSCLC). The study primary endpoints are PFS per RECIST v. 1.1 and safety. KEAP1/NRF2&#xD;
      mutation status (for eligibility) and STK11/LKB1 status (for stratification) will be&#xD;
      determined by next generation sequencing. A commercial liquid biopsy (circulating tumor DNA)&#xD;
      NGS test will be provided to study participants free of charge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Duration of investigator-determined PFS per RECIST v1.1 in the intent-to-treat (ITT) population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0</measure>
    <time_frame>Up to 55 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for Patients Treated with Telaglenastat plus Standard-of-Care Pembrolizumab and Chemotherapy versus Placebo plus Standard-of-Care Pembrolizumab and Chemotherapy</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for Patients Treated with Telaglenastat plus Standard-of-Care Pembrolizumab and Chemotherapy versus Placebo plus Standard-of-Care Pembrolizumab and Chemotherapy</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR is defined as the duration of response for patients achieving a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in the Subgroup of Patients with Biochemical Evidence of Activation of the NRF2 Pathway</measure>
    <time_frame>Up to 55 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-squamous Non-small-cell Lung Cancer</condition>
  <condition>Non-Squamous Non-Small Cell Neoplasm of Lung</condition>
  <condition>KEAP1 Gene Mutation</condition>
  <condition>NRF2 Gene Mutation</condition>
  <condition>NFE2L2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaglenastat</intervention_name>
    <description>Oral Glutaminase Inhibitor</description>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>CB-839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin Chemotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Chemotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab Immunotherapy</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <other_name>Oral placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid 400 -1000 μg</intervention_name>
    <description>Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12 1000 μg</intervention_name>
    <description>Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg</intervention_name>
    <description>For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.</description>
    <arm_group_label>Placebo with Pembrolizumab and Chemotherapy</arm_group_label>
    <arm_group_label>Telaglenastat with Pembrolizumab and Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented non-squamous NSCLC&#xD;
&#xD;
          2. Stage IV (M1a-c, AJCC 8th Edition, Amin 2017) disease not previously treated with&#xD;
             systemic therapy for metastatic NSCLC&#xD;
&#xD;
             a. Patients who received adjuvant or neo-adjuvant therapy (with or without&#xD;
             immunotherapy) for localized NSCLC are eligible if all adjuvant/neo-adjuvant therapy&#xD;
             (including immunotherapy) was completed at least 6 months prior to the development of&#xD;
             metastatic disease.&#xD;
&#xD;
          3. No known actionable mutation in EGFR, ALK, ROS1, BRAF, NTRK or other known actionable&#xD;
             mutation for which there is approved therapy in the first-line lung cancer setting&#xD;
&#xD;
          4. Must have at least one radiographically measurable lesion per RECIST v1.1 defined as a&#xD;
             lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis&#xD;
             imaged by computed tomography (CT) scan or magnetic resonance imaging (MRI)&#xD;
&#xD;
             a. Target lesions situated in a previously irradiated area may be considered&#xD;
             measurable if progression has been demonstrated subsequent to radiation therapy&#xD;
&#xD;
          5. Age ≥ 18 years on the day of signing informed consent&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Estimated life expectancy of at least 3 months&#xD;
&#xD;
          8. Recovery to baseline or ≤ grade 1 National Cancer Institute (NCI) Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to the prior&#xD;
             treatment, unless after discussion with the medical monitor, the AE(s) are deemed&#xD;
             clinically non-significant and/or stable on supportive therapy&#xD;
&#xD;
          9. Has sponsor-approved eligible mutation in KEAP1 or NRF2 documented by NGS from a&#xD;
             CAP-accredited and/or CLIA-certified laboratory (study-provided NGS or other NGS) and&#xD;
             STK11 mutation status is known for the purpose of stratification.&#xD;
&#xD;
         10. Adequate organ function laboratory findings (defined per protocol)&#xD;
&#xD;
         11. Reproductive status:&#xD;
&#xD;
             a. A female patient of childbearing potential must: i. Have a negative serum pregnancy&#xD;
             test within 7 days prior to randomization ii. Agree to use methods of contraception&#xD;
             outlined in Section 8.1.2 during the study through 120 days following the last dose of&#xD;
             telaglenastat or pembrolizumab, or through 180 days following the last dose of&#xD;
             chemotherapeutic drugs iii. Postmenopausal females (no menses for &gt; 1 year without an&#xD;
             alternate medical cause) and surgically sterilized females are exempt from these&#xD;
             requirements b. Male patients who are sexually active with heterosexual partners of&#xD;
             childbearing potential must agree to contraceptive requirements outlined in Section&#xD;
             8.1.2 and refrain from donating sperm during the study through 120 days following the&#xD;
             last dose of telaglenastat or pembrolizumab, or through 180 days following the last&#xD;
             dose of chemotherapeutic drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Squamous cell histology and mixed histology tumors with any small-cell/neuroendocrine&#xD;
             component (other mixed histology should be reviewed with the medical monitor for&#xD;
             eligibility)&#xD;
&#xD;
          2. Any other concurrent malignancy requiring local or systemic therapy. Patients with&#xD;
             other previously treated malignancy(ies) are allowed if the specific neoplasm, in the&#xD;
             opinion of the principal investigator and with the agreement of the medical monitor,&#xD;
             is not expected to interfere with study-specific endpoints&#xD;
&#xD;
          3. Radiation therapy to the lung &gt; 30 Gy within 6 months prior to randomization&#xD;
&#xD;
          4. Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal&#xD;
             obstruction, abdominal carcinomatosis&#xD;
&#xD;
          5. Active autoimmune disease that has required systemic treatment in past 2 years (i.e.,&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs)&#xD;
&#xD;
             a. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          6. Treatment with chronic systemic steroids greater than 10 mg equivalent of prednisone&#xD;
             per day&#xD;
&#xD;
          7. Unstable/inadequate cardiac function, defined as the following:&#xD;
&#xD;
               1. Myocardial infarction or symptomatic ischemia within 6 months prior to&#xD;
                  randomization&#xD;
&#xD;
               2. Uncontrolled or clinically significant conduction abnormalities (e.g., patients&#xD;
                  with ventricular tachycardia on anti-arrhythmics are excluded; patients with 1st&#xD;
                  degree atrioventricular [AV] block or asymptomatic left anterior fascicular block&#xD;
                  [LAFB]/right bundle branch block [RBBB] are eligible)&#xD;
&#xD;
               3. Congestive heart failure (New York Heart Association class III to IV)&#xD;
&#xD;
          8. Unable to swallow oral medications&#xD;
&#xD;
          9. Known sensitivity to any component of the study treatment (pembrolizumab, carboplatin,&#xD;
             pemetrexed, and/or telaglenastat) or previous severe hypersensitivity to another&#xD;
             monoclonal antibody (mAb)&#xD;
&#xD;
         10. Unable or unwilling to take folic acid or vitamin B12 supplementation (per pemetrexed&#xD;
             label)&#xD;
&#xD;
         11. Unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) as&#xD;
             specified in pemetrexed label&#xD;
&#xD;
         12. Interstitial lung disease or a history of pneumonitis that required oral or&#xD;
             intravenous glucocorticoid treatment&#xD;
&#xD;
         13. Unable or unwilling to discontinue proton pump inhibitor (PPI) use ≥ 5 days prior to&#xD;
             randomization&#xD;
&#xD;
         14. Patient known to be positive for Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
         15. Known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg&#xD;
             result. Active Hepatitis C is defined by a known positive Hepatitis C antibody result&#xD;
             and known quantitative Hepatitis C virus RNA results greater than the lower limits of&#xD;
             detection of the assay. Patients receiving antiviral therapy for Hepatitis B or C also&#xD;
             are not eligible&#xD;
&#xD;
         16. Any condition including social, psychiatric or medical (including uncontrolled&#xD;
             significant concurrent illness) that in the opinion of the Investigator could&#xD;
             interfere with treatment or protocol-related procedures&#xD;
&#xD;
         17. Regular use of illicit drugs or history (within past year) of substance abuse&#xD;
             (including alcohol)&#xD;
&#xD;
         18. Patients who are pregnant or lactating&#xD;
&#xD;
         19. Major surgery &lt; 3 weeks prior to randomization. In addition, patients with ongoing&#xD;
             clinically relevant complications from prior surgery are not eligible and they must&#xD;
             have recovered adequately from the toxicity and/or complications from the intervention&#xD;
             prior to starting study treatment&#xD;
&#xD;
         20. Any radiation therapy within 2 weeks prior to randomization (with exception of SRS for&#xD;
             brain metastases). In addition, patients with ongoing clinically relevant&#xD;
             complications from prior radiation therapy, patients requiring corticosteroids to&#xD;
             treat radiation toxicity and patients who developed radiation pneumonitis are not&#xD;
             eligible.&#xD;
&#xD;
         21. Symptomatic ascites or pleural effusion. Patients who are clinically stable following&#xD;
             treatment for these conditions (including therapeutic thoraco- or paracentesis) are&#xD;
             eligible&#xD;
&#xD;
         22. Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant&#xD;
             small bowel resection or gastric bypass surgery, use of feeding tubes or other&#xD;
             situation that may preclude adequate absorption or oral study drug&#xD;
&#xD;
         23. Infection requiring more than 5 days of parenteral antibiotics, antivirals, or&#xD;
             antifungals within two weeks prior to randomization. Anti-infective therapy must be&#xD;
             completed at least 7 days before randomization&#xD;
&#xD;
         24. Patients with active and/or untreated central nervous system metastasis including&#xD;
             carcinomatous meningitis (leptomeningeal disease) are not eligible. Patients with&#xD;
             previously treated brain metastases are eligible if they meet the following criteria:&#xD;
&#xD;
               1. Received definitive treatment with stereotactic radiosurgery (SRS) or surgery to&#xD;
                  all known central nervous system (CNS) lesions (whole brain radiotherapy is not&#xD;
                  an eligible modality)&#xD;
&#xD;
               2. Be at least 4 weeks post-surgical resection of CNS disease, symptomatically&#xD;
                  stable and off steroids before randomization&#xD;
&#xD;
         25. Any live-virus vaccination within 28 days prior to randomization. Examples of live&#xD;
             vaccines include, but are not limited to, the following: measles, mumps, rubella,&#xD;
             varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG),&#xD;
             and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed&#xD;
             virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist&#xD;
             ®) are live attenuated vaccines and are not allowed&#xD;
&#xD;
         26. Has had an allogeneic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil Kuriakose, MD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama - Mitchell Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuma Regional Medical Center</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine, Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare - Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital - Bines Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - South (SCRI)</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Hospital West</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - North (SCRI)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - Panhandle (SCRI)</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - East (SCRI)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology of Northshore</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Health</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (KUMC)</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchartrain Cancer Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology - USOR</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Health - James M. Stockman Cancer Institute</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital (West Michigan Cancer Center)</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital Cancer Care Center</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A.</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Cancer Care and Blood Disorders (NJCCBD)</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital - Luckow Pavilion</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. (400 Patoon Creek Blvd.)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. (43 New Scotland Ave.)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pelmutter Cancer Center at Winthrop</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone (NYU)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cone Health at Alamance Regional</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriHealth Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute (OCSRI)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>92713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU) Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University Milton S. Hershey Medical Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga (SCRI)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Beaumont - USOR</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denison</name>
      <address>
        <city>Denison</city>
        <state>Texas</state>
        <zip>75020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>770390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology of South Texas</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialist</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University (VCU) Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Wytheville</city>
        <state>Virginia</state>
        <zip>24382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Care Alliance (SCCA)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialities</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin (MCW)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>KEAP1</keyword>
  <keyword>NRF2</keyword>
  <keyword>NFE2l2</keyword>
  <keyword>LKB1</keyword>
  <keyword>STK11</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>NGS</keyword>
  <keyword>Mutation</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>Telaglenastat</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Glutaminase</keyword>
  <keyword>Glutathione</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Front-line</keyword>
  <keyword>First-line</keyword>
  <keyword>Non-squamous</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Alimta</keyword>
  <keyword>Guardant360</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

